Clinical Trial Update: ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers [Phase 1]

View source ↗

Summary

This update describes a Phase 1 trial evaluating ETC-159 in combination with pembrolizumab for advanced MSS/pMMR platinum-resistant ovarian cancer, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ETC-159
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer | Phase 1 | Status: RECRUITING